Limits...
MicroRNAs in urine are not biomarkers of multiple myeloma.

Sedlaříková L, Bešše L, Novosadová S, Kubaczková V, Radová L, Staník M, Krejčí M, Hájek R, Ševčíková S - J Negat Results Biomed (2015)

Bottom Line: We found 20 deregulated microRNA (p < 0.05); for further validation, we chose 8 of them.Nevertheless, only differences in expression levels of miR-22-3p remained close to statistical significance.Our preliminary results did not confirm urine microRNA as a potential biomarker for multiple myeloma.

View Article: PubMed Central - PubMed

Affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. lena.sedlarikova@gmail.com.

ABSTRACT

Background: In this study, we aimed to identify microRNA from urine of multiple myeloma patients that could serve as a biomarker for the disease.

Results: Analysis of urine samples was performed using Serum/Plasma Focus PCR MicroRNA Panel (Exiqon) and verified using individual TaqMan miRNA assays for qPCR. We found 20 deregulated microRNA (p < 0.05); for further validation, we chose 8 of them. Nevertheless, only differences in expression levels of miR-22-3p remained close to statistical significance.

Conclusions: Our preliminary results did not confirm urine microRNA as a potential biomarker for multiple myeloma.

Show MeSH

Related in: MedlinePlus

Comparison of expression levels of validated miRNAs defined as logarithmic values of 2-ΔCt normalized to cel-miR-39 expression levels for MM, RCC patients and HD. a – miR-29a-3p; b – miR-29b-3p; c – miR-29c-3p; d miR-25-3p; e – miR-22-3p; f – miR-106b-5p; g – miR-18a-3p; h – miR-200c-3p
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4581458&req=5

Fig2: Comparison of expression levels of validated miRNAs defined as logarithmic values of 2-ΔCt normalized to cel-miR-39 expression levels for MM, RCC patients and HD. a – miR-29a-3p; b – miR-29b-3p; c – miR-29c-3p; d miR-25-3p; e – miR-22-3p; f – miR-106b-5p; g – miR-18a-3p; h – miR-200c-3p

Mentions: Screening of miRNA in urine revealed 20 deregulated miRNAs (p < 0.05 for all miRNAs) between MM and HD (Fig. 1). For further validation, we chose 8 most deregulated miRNAs between MM and HD: miR-200c-3p, miR-29b-3p, miR-29c-3p, miR-22-3p, miR-29a-3p, miR-25-3p, miR-106b-5p, miR-18a-3p (Table 1). Expression levels of these miRNAs were further verified on a larger cohort of MM patients, RCC patients and HD. Results from validation revealed that expression levels of chosen miRNAs from urine of MM patients are not statistically different (p = 0.05) from HD and RCC patients (Fig. 2). Results from validation did not confirm statistical significance from the screening. Only differences in expression levels of miR-22-3p between MM patients and HD in urine (p = 0.090) remained close to statistical significance (Table 2).Fig. 1


MicroRNAs in urine are not biomarkers of multiple myeloma.

Sedlaříková L, Bešše L, Novosadová S, Kubaczková V, Radová L, Staník M, Krejčí M, Hájek R, Ševčíková S - J Negat Results Biomed (2015)

Comparison of expression levels of validated miRNAs defined as logarithmic values of 2-ΔCt normalized to cel-miR-39 expression levels for MM, RCC patients and HD. a – miR-29a-3p; b – miR-29b-3p; c – miR-29c-3p; d miR-25-3p; e – miR-22-3p; f – miR-106b-5p; g – miR-18a-3p; h – miR-200c-3p
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4581458&req=5

Fig2: Comparison of expression levels of validated miRNAs defined as logarithmic values of 2-ΔCt normalized to cel-miR-39 expression levels for MM, RCC patients and HD. a – miR-29a-3p; b – miR-29b-3p; c – miR-29c-3p; d miR-25-3p; e – miR-22-3p; f – miR-106b-5p; g – miR-18a-3p; h – miR-200c-3p
Mentions: Screening of miRNA in urine revealed 20 deregulated miRNAs (p < 0.05 for all miRNAs) between MM and HD (Fig. 1). For further validation, we chose 8 most deregulated miRNAs between MM and HD: miR-200c-3p, miR-29b-3p, miR-29c-3p, miR-22-3p, miR-29a-3p, miR-25-3p, miR-106b-5p, miR-18a-3p (Table 1). Expression levels of these miRNAs were further verified on a larger cohort of MM patients, RCC patients and HD. Results from validation revealed that expression levels of chosen miRNAs from urine of MM patients are not statistically different (p = 0.05) from HD and RCC patients (Fig. 2). Results from validation did not confirm statistical significance from the screening. Only differences in expression levels of miR-22-3p between MM patients and HD in urine (p = 0.090) remained close to statistical significance (Table 2).Fig. 1

Bottom Line: We found 20 deregulated microRNA (p < 0.05); for further validation, we chose 8 of them.Nevertheless, only differences in expression levels of miR-22-3p remained close to statistical significance.Our preliminary results did not confirm urine microRNA as a potential biomarker for multiple myeloma.

View Article: PubMed Central - PubMed

Affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. lena.sedlarikova@gmail.com.

ABSTRACT

Background: In this study, we aimed to identify microRNA from urine of multiple myeloma patients that could serve as a biomarker for the disease.

Results: Analysis of urine samples was performed using Serum/Plasma Focus PCR MicroRNA Panel (Exiqon) and verified using individual TaqMan miRNA assays for qPCR. We found 20 deregulated microRNA (p < 0.05); for further validation, we chose 8 of them. Nevertheless, only differences in expression levels of miR-22-3p remained close to statistical significance.

Conclusions: Our preliminary results did not confirm urine microRNA as a potential biomarker for multiple myeloma.

Show MeSH
Related in: MedlinePlus